IDEA-FAST’s Post

Here is a simulation of my own beating heart, developed by @ELEM Biotech. Why are we developing Virtual Human Twins, and in particular hearts? ❤️ As the @World Heart Federation highlights, cardiovascular disease (CVD) is the leading cause of death worldwide, claiming more than 20.5 million lives every year. Replicating the complex environment of CVD for drug testing presents a major challenge because of its heterogeneity - factors such as comorbidities, age, and gender all impact drug efficacy. Additionally, the progressive nature of CVDs makes it difficult to predict long-term outcomes based solely on short-term trial data. This is where ELEM’s #VirtualHearts play a crucial role. By testing drugs using our innovative technology, we enable pharmaceutical companies to design SMART trials that account for population variability and pave the way for more effective and personalised treatments. 🌍 Want to contribute to the fight against CVD? Help raise awareness about its impact and promote small lifestyle changes, like better diet, exercising, and stress management, that can improve heart health. #CardiovascularHealth #UseHeart #VirtualHumanTwins #SMARTtrials #UseVirtualHearts

This August, let's raise awareness about #Gastroparesis. Unlike occasional indigestion, it causes persistent issues like nausea, vomiting, abdominal pain, and weight loss. If you experience these symptoms, you're not alone. Biopharma Informatic is at the forefront of research seeking not just advancements but ultimately leading to the development of more targeted therapies for gastroparesis. Your participation in our studies can be incredibly valuable. Stay informed and join us in the fight for better solutions! #GastroparesisResearch #DigestiveHealth #GPAwarenessMonth #HoustonMedicalResearch #clinicaltrials #research

The hidden dangers of prediabetes   Not only can the condition lead to diabetes, but it also increases your risk for cardio-vascular, kidney, and liver disease.   https://lnkd.in/e4-geiYJ   The article highlights the significant health risks associated with prediabetes and its progression to type 1 diabetes, a condition that remains challenging to manage. Advances in regenerative medicine, such as the CELZ-201 treatment being studied in the CREATE-1 clinical trial, aim to address the underlying causes of type 1 diabetes. By focusing on immunomodulation and improving immune regulation, this approach seeks to provide hope for patients impacted by the disease.    As research progresses, efforts by Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) to improve patient outcomes and manage the complications associated with diabetes continue to grow in importance.    For more information on the CELZ-201 trial, visit https://lnkd.in/eutVZQcX #creativemedical #celz #nasdaq #biotech

Healthcare is changing - and that’s a good thing. A one-size-fits-all model of care is not working and now, we have the technology to approach our health with nuance, personalization, and continuous data in a way that wasn’t possible years ago. The future of healthcare centers around a model for preventative care that is multi-faceted and unique to each individual. True innovation is driven by providers who are implementing multidimensional care and using integrated technology to empower people to make changes to their daily behavior that improve health and well-being. That’s why we're excited to work with the folks meta[bolic] As a leading hybrid therapeutics company with brands like GluCare.Health and Zone.Health, they are dedicated to delivering superior outcomes in chronic metabolic disease management, including diabetes, obesity, and prediabetes. Through this partnership, we’ll see Oura Ring being used in a clinical setting and learn how continuous data monitoring can impact outcomes. We’re also embarking on research initiatives together that will change how we think about preventative care, with the goal of proving how effective a new model of care can be. #WithOura

The hidden dangers of prediabetes   Not only can the condition lead to diabetes, but it also increases your risk for cardio-vascular, kidney, and liver disease.   https://lnkd.in/ePRuM_bD   The article highlights the significant health risks associated with prediabetes and its progression to type 1 diabetes, a condition that remains challenging to manage. Advances in regenerative medicine, such as the CELZ-201 treatment being studied in the CREATE-1 clinical trial, aim to address the underlying causes of type 1 diabetes. By focusing on immunomodulation and improving immune regulation, this approach seeks to provide hope for patients impacted by the disease.    As research progresses, efforts by Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) to improve patient outcomes and manage the complications associated with diabetes continue to grow in importance.    For more information on the CELZ-201 trial, visit https://lnkd.in/eZ8FAwYB #creativemedical #celz #nasdaq #biotech

The pathophysiology of endometriosis remains unclear. Retrograde menstruation could be a phenomenon that initiates the process, but may not explain the entire pathophysiology of endometriosis. Current evidence suggests that endometriosis is a type of chronic inflammatory disease. In this new Commentary paper, Togas Tulandi and Paolo Vercellini emphasize the importance of pursuing research for novel and safer anti-inflammatory and immunomodulatory drugs that can be used by patients with endometriosis on a long-term basis. The Commentary is free to read from our in-press articles section now https://lnkd.in/evWif8pc #RBMOcommentary #Endometriosis #RetrogradeMenstruation #Pathophysiology #Atherosclerosis #CardiovascularDisease #Endometriosis #EndometriosisMarkers #Inflammation

Summary: The article covers various health news stories, including the FDA approval of a new Alzheimer's drug called donanemab, the potential link between weight loss drugs and cancer risk, and the investigation of illnesses and possible death related to "microdosing" candies containing the amanita mushroom-derived chemical muscimol. Hashtags: #HealthNews #AlzheimersDrug #WeightLoss #CancerRisk #MicrodosingCandies Read more here: https://lnkd.in/eMnncvYi BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

New Consensus on Hemoadsorption Therapy for Rhabdomyolysis! 🚀 We’re glad to share the latest expert consensus on using CytoSorb® in rhabdomyolysis, published in BMC Nephrol. 🔍 Key Takeaways: - Results: CytoSorb® prevents and reduces Acute Kideny Injury (AKI) led by excessive concentration of myoglobin - Patients profile: myoglobin >10.000ng/ml: use Cytosorb® within 12-24 h from diagnosis - Therapy: change sorbent every 8-12 h until myoglobin levels are stably <5.000 ng/ml The Hemoadsorbtion Rhabdomyolysis Task Force's findings confirm the effectiveness of CytoSorb® in reducing myoglobin. 👉 https://bit.ly/3Xu31MW Don’t forget our 𝐂𝐚𝐥𝐥 𝐟𝐨𝐫 𝐀𝐛𝐬𝐭𝐫𝐚𝐜𝐭𝐬: present your research at the 𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝐏𝐮𝐫𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 in Milan, September 26ᵗʰ and 27ᵗʰ, 2025. Submit your abstract here purification.therapies@aferetica.com #Aferetica #ScientificLiterature #CriticalCare #WPT #Healthcare

There is growing promise and interest in using CAR-T therapy for autoimmune diseases like lupus, myositis, and systemic sclerosis. Recent research has shown positive results, with some patients experiencing remission and reduced need for other medications. While these early findings are encouraging, there are still challenges to overcome, such as the high cost, complexity of manufacturing, and potential long-term health issues. The ultimate goal is to achieve lasting remission for patients with autoimmune diseases and reduce their dependence on immunosuppressive drugs. #AutoimmuneTherapies #CellTherapy #LupusResearch #InflammatoryDiseases #CAR-TTreatment Read more here: https://lnkd.in/euGTizeM BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

Our Director of Aging Services, Sam Van Kalkeren, recommends exploring this promising study on a GLP-1 drug, liraglutide, which has shown potential in slowing cognitive decline in mild Alzheimer’s disease. The research suggests an 18% reduction in decline over a year, offering new possibilities for those affected. Read the full article below, and follow us for more industry insights! https://brnw.ch/21wNgAp #Alzheimers #AgingServices #AlzheimersResearch